
Pfizer's Irish staff worry about more job losses as drugmaker announces another €1.5bn in cuts
Pfizer
said it will cut another $1.7 billion (€1.5 billion) in costs by the end of 2027. This is the third round of cuts announced by the US pharma group in the last three years and brings to $7.7 billion the amount it hopes to save in annual costs.
The company said it expected to make additional savings of $1.2 billion by increased use of automation, artificial intelligence and other digital tools. A further $500 million in savings will come from its research and development budget.
The new cuts come as the drugmaker struggles to find sources of growth amid declining demand for its vaccine and treatment for Covid-19. Pfizer is expected to lose more than $15 billion in revenue by the end of the decade as top products lose patent protection.
READ MORE
A series of multibillion-dollar acquisitions has yet to yield new blockbusters and Pfizer's stable of drugs in development has failed to convince Wall Street, with the company most recently pulling the plug on an experimental pill for obesity.
'Investors are just not excited about the current Pfizer business or the pipeline,' said Mizuho analyst Jared Holz. 'You could argue that nothing that they've done over the past few years has really worked, and to just watch your stock make new multiyear lows, that can't be the endgame here.'
The company, which employs some 5,000 people in Ireland, announced last October that it was cutting about 5 per cent of its Irish workforce, with about 210 jobs going across three sites: Grange Castle, West Dublin; Newbridge, Co Kildare; and Ringaskiddy, Co Cork.
It also shed 100 staff from its Newbridge site in late 2023 in response to a global collapse in sales of its Paxlovid Covid antiviral medicine.
It is unclear whether the latest cost savings plan with its emphasis on automation will mean further job losses in Ireland.
Patrick Guilbaud on bringing fine dining to Ireland, retirement plans, and not getting that third Michelin star
Listen |
47:51
The announcement came alongside publication of the drugmaker's first quarter results, with revenue of $13.7 billion falling short of analysts' $14 billion average estimate. Adjusted earnings were 92 US cents per share.
Pfizer is maintaining its 2025 outlook of between $61 billion and $64 billion and adjusted per-share earnings of $2.80 a share to $3 a share. Chief financial officer David Denton said the company is 'trending towards the upper end' of the per-share earnings guidance range.
That wasn't enough to encourage investors initially with Pfizer's shares slipping as much as 2.6 per cent after the markets opened in New York. But sentiment improved as the results were digested with the shares trading up 3.4 per cent in early afternoon trade.
Mr Denton told analysts on Tuesday that the company is forecasting $150 million in costs this year from the tariffs implemented to date. He said the sum was factored into the company's sales and earnings outlook for the year.
Pfizer, which relies on a global network of manufacturing sites to supply drugs to the US, could be significantly affected by Trump's promised tariffs on pharmaceuticals. Chief executive Albert Bourla has said the company could mitigate part of the impact by moving some overseas production into the US.
He said the industry is hoping the Trump administration will focus more on generic medicines like those the World Health Organisation has designated as essential, which tend to be produced mostly in China and India.
'I think that's where the problem is. It's not if an obesity drug is made in Ireland,' he said.
Speaking on a conference call with investors, he said the drugmaker's story over the next three years would not be one of strong revenue growth, given looming patent expirations on top products, but rather one of earnings growth.
The company's Covid business, which once drove annual revenue to $100 billion, has dramatically faded since the heights of the pandemic.
In the first quarter, Covid sales overall dragged on sales. Pfizer's Covid vaccine revenue was $565 million, beating estimates of $325 million. But Paxlovid, the company's pill for Covid, brought in $491 million, far below Wall Street's $902 million forecast.
As for other drugs, sales of Eliquis, the company's decade-old blood thinner and one of its top drugs, were $1.92 billion, roughly in line with estimates. The pneumonia vaccine Prevnar added $1.66 billion, meeting analysts' average view.
Sales of the heart drug Vyndaqel were $1.49 billion on the quarter, beating estimates of $1.38 billion despite mounting competition from BridgeBio Pharma and Alnylam Pharmaceuticals. – Additional reporting: Bloomberg
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Journal
40 minutes ago
- The Journal
Charlie Bird's wife supporting All-Ireland morning walk in aid of Motor Neurone Disease
THE PUBLIC HAVE been urged to come together and walk 'shoulder to shoulder' by joining a sponsored walk on Sunday, the day of the All-Ireland football final. The walk will take place in Offaly. Organised by a group of Irish sports stars and sporting clubs, the 'Shoulder to Shoulder' walk is in aid of those suffer from ALS, the most common form of Motor Neurone Disease. It will begin the morning of the final at St Brigid's GAA Club, Croghan, Co Offaly starting at 9am. The wife of Charlie Bird, Claire Bird, is supporting the cause. Charlie, the former chief news correspondent with RTÉ, was diagnosed with motor neurone disease in 2021 and passed away in March last year. He raised €3.6m in aid of the Irish Motor Neurone Disease Association and Pieta before his death. Claire said that there is now more awareness around MND and progress has been made in improving the quality of life for ALS sufferers and their families, but 'more is needed'. 'In particular, funds are urgently needed to discover the cause and potential treatments for this cruel disease and that's what we are asking for today. Advertisement 'Every donation and every act of support will make a difference in the fight against ALS and MND so please, wear your jersey for your teammate on 27 July and donate whatever you can afford to support the research that will bring hope to future generations.' One of the organisers of the walk, former Galway GAA player Michael Meehan, said, 'All Ireland Final day is a special day in Irish sport and on this special day, we call on you to join us in a heartfelt show of solidarity to support all our 'teammates' who are facing ALS.' He invited everyone to wear their jerseys and join the walk on the morning of the All-Ireland. 'Anyone who can't join the walk can still support the cause by donating to iDonate and all funds will go towards Research Motor Neurone,' Michael added. The walk is to raise funds for Research Motor Neurone, an Irish charitable organisation, led by Orla Hardiman, Professor of Neurology at Trinity College Dublin, and an international authority on Motor Neurone Disease and related neurodegeneration. MND is a progressive neurological condition in which the nerves that control voluntary muscles stop working. In Ireland, around 155 people are newly diagnosed with the condition every year; there are currently more than 470 people living with MND and ALS in Ireland. It is a challenging and debilitating disease for which there is currently no cure. Galway GAA, Mountbellew-Moylough GAA, Cu Chulainns GAA (London), Leinster Rugby, [Connacht Rugby], Ireland U20 Rugby, Garbally College are among those supporting the walk. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal

The 42
2 hours ago
- The 42
Next year's Women's Irish Open to take place at The K Club
THE 2026 WOMEN'S Irish Open will be played at The K Club, the Ladies European Tour (LET) has confirmed. The championship will take place in Co. Kildare from 27-30 August on the club's Palmer South Course, which has previously hosted three European Opens. Advertisement The Women's Irish Open, which will again have KPMG as its title sponsor, has been moved back to August to offer players 'a prime opportunity to compete in front of passionate Irish crowds in the build-up to the Solheim Cup', the LET said. 'Tournament organisers are confident that this new venue will attract even bigger names and further elevate the fan experience.' Early-bird tickets for the 2026 KPMG Women's Irish Open will go on sale in due course, with U16s once again able to attend for free. MJ Fetherston, director of The K Club said: 'This is a tournament we want to support and elevate. There is so much brilliant talent in women's golf. We have been supporting Leona Maguire for the past few years and this is a terrific development on that. 'The Palmer South course has been given a lot of love and energy over the past few years. We are excited to bring tournament golf back to this challenging course. 'Our family and the whole team at the resort want to make this the best Women's Irish Open yet.'

The Journal
3 hours ago
- The Journal
Government urged ‘not to delay solemn promise' of VAT cut for hospitality sector
THE GOVERNMENT HAS been urged 'not to delay its promise' of cutting the VAT rate for the hospitality sector to 9% in the upcoming budget. Despite election promises and ministerial pronouncements, government this week has been signalling that a cut to the VAT rate for the hospitality sector may not go ahead in Budget 2026. Tánaiste Simon Harris said the government had made a 'solemn' commitment in the election to reduce the VAT rate for the hospitality sector, but this week the government has been sending mixed signals on how it will proceed. Speaking to RTÉ Radio 1 yesterday, junior justice minister Niall Collins said the VAT cut was not a 'done deal'. VAT for the tourism and hospitality sectors was reduced to 9% during the Covid-19 pandemic at a cost of €1.2bn to the exchequer. The previous 13.5% rate was reinstated last August, despite the sector's opposition. Retail Excellence Ireland (REI), the largest representative body for the retail industry in Ireland, has called on the Government to follow through on its 'promise to permanently cut the rate of VAT for the hospitality industry to 9% in Budget 2026'. Jean McCabe, CEO of REI, said that 'after a tough few years, the Government's solemn promise to cut the VAT rate for the hospitality industry was welcome'. 'It would be regrettable for it to delay its promise now,' she added. 'There are too many livelihoods at stake not to introduce a measure as soon as possible that would have such a significant impact on the industry, and on related industries such as retail.' She said the government must do 'everything in its power to strengthen our domestic economy at a time when we need it most'. McCabe also called for the general rate of VAT be cut from 23% to 21% to assist the retail industry. Advertisement Meanwhile, the Irish Hotels Federation (IHF) has criticised the 'deeply misleading' figure of €1 billion per year that was quoted earlier this week regarding the cost to the Exchequer of reducing VAT for hospitality businesses. On Tuesday, during a press conference on the Summer Economic Statement, Minister for Finance Paschal Donohoe told reporters that the one-year cost for reducing the hospitality VAT rate to 9% for restaurants and hotels would be between €950mn and €1bn. However, later in the press conference, Donohoe said he would need to clarify if that figure did include hotels. A spokesperson for the minister told The Journal today that, based on CSO data, the total one-year cost for restaurants and hotels is actually €810mn. This is split €675mn for restaurants and cafes and €135mn for hotels. The cost for hairdressers would be an additional €40mn. IHF Chief Executive Paul Gallagher said it's time for an 'honest and balanced debate' that 'recognises the economic and social importance of hospitality food service businesses and gives them a fighting chance to survive'. He noted that the 'true cost involved is significantly lower than the widely quoted €1bn figure cited by the Government in recent days' Gallagher added: 'The Government's narrative has had the effect, intended or otherwise, of driving a wedge between the public and the hospitality industry, framing the VAT reduction as a giveaway to businesses. 'This is extremely divisive and simply not true.' He said the 9% VAT reduction sought would apply to prepared food services, such as meals in restaurants, takeaways, commercial kitchens and food served on transport. 'The real beneficiaries are small food businesses,' said Gallagher, 'many of which are operating on the brink of survival due to extreme food cost inflation and shrinking margins. 'Reducing VAT on food services is not a handout to hospitality businesses – it is a vital intervention for a sector that supports over 270,000 livelihoods and contributes significantly to the economy.' Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal